Bavarian Nordic expects revenue setback in 2022

Key 2021 figures from Bavarian Nordic’s annual report are in line with projections, but scrape the bottom of previous estimations. 2022 will be a year of investments for the biotech company, which is why an operating deficit is already being forecasted.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

Biotech company Bavarian Nordic almost made a comeback in 2021 – but not quite.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading